ALK and non-small cell lung carcinoma: Approximately 3–7% of patients with NSCLC harbour rearrangements in the anaplastic lymphoma kinase (ALK) gene, a potent oncogenic driver [3], and ALK tyrosine kinase inhibitors (TKIs) have markedly improved the survival of these patients.